The success of the Polypill, which has been sold in large volumes at low prices, paved the way for its controversial successor, the TetraTab, which contains derivatives of modafinil and fluoxetine and ...

The CV-Polypill is a dominant strategy in secondary cardiovascular prevention, compared with standard care, from the Spanish healthcare perspective. The CV-Polypill should be considered as a secondary ...

Introduction: A promising concept in cardiovascular disease prevention (the polypill) was introduced in 2003. Although the polypill may seem as an effective intervention, data on its costs and cost ...

Objectives To understand the perspectives of stroke survivors, caregivers and general practitioners (GPs) on a polypill approach, consisting of blood pressure and cholesterol-lowering therapies, with ...

The FDA has approved Widaplik, a polypill combining telmisartan, amlodipine, and indapamide, for the treatment of hypertension in adults, including as initial therapy. This is the first ...

The FDA has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.

The FDA approved a polypill containing telmisartan, amlodipine, and indapamide, known as Widaplik, for the treatment of hypertension in adults, including as initial treatment.